Myricx Bio

London, United Kingdom

Myricx Bio is a biotechnology company that develops novel NMT inhibitor payloads for ADCs to treat cancer.

$115.3M raised

Jul 2024

Series A

Top Investors

Eli LillyBrandon CapitalNovo HoldingsSofinnova PartnersAbingworth

19,000+ verified contacts

Emails, phones & LinkedIn profiles

How much funding has Myricx Bio raised?

Myricx Bio has raised $115.3M in total funding. The most recent round was Series A. The last funding was announced in July 2024.

Who are Myricx Bio's investors?

Myricx Bio's investors include Eli Lilly, Brandon Capital, Novo Holdings, Sofinnova Partners, Abingworth.

Where is Myricx Bio headquartered?

Myricx Bio is headquartered in London, United Kingdom.

What does Myricx Bio do?

Myricx Bio is a biotechnology company that develops novel NMT inhibitor payloads for ADCs to treat cancer.

What stage is Myricx Bio at?

Myricx Bio is at the Series A stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated July 8, 2024.

MLA

"Myricx Bio — Funding & Investors." VCBacked, July 8, 2024, https://www.vcbacked.co/company/myricx-bio. Accessed June 7, 2026.

APA

VCBacked. (2024). Myricx Bio — Funding & Investors. Retrieved June 7, 2026, from https://www.vcbacked.co/company/myricx-bio

Wikipedia (cite web)

{{cite web |title=Myricx Bio — Funding & Investors |url=https://www.vcbacked.co/company/myricx-bio |website=VCBacked |access-date=June 7, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated July 8, 2024.